“Assessment of Pressor Effects of Drugs”—A New US FDA Draft Guidance for Industry

被引：0
|
作者：
J. Rick Turner
机构：
来源：
Therapeutic Innovation & Regulatory Science | 2018年 / 52卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：397 / 399
页数：2
相关论文
共 50 条
  • [21] 8th GCC: Consolidated feedback to US FDA on the 2013 Draft FDA Guidance on Bioanalytical Method Validation
    Bower, Joseph
    Fast, Douglas
    Garofolo, Fabio
    Gouty, Dominique
    Hayes, Roger
    Lowes, Steve
    Nicholson, Robert
    LeLacheur, Richard
    Bravo, Jennifer
    Shoup, Ronald
    Dumont, Isabelle
    Carbone, Mary
    Zimmer, Jennifer
    Ortuno, Jordi
    Cruz Caturla, Maria
    Datin, Jim
    Lansing, Tim
    Fatmi, Saadya
    Struwe, Petra
    Sheldon, Curtis
    Islam, Rafiqul
    Yu, Mathilde
    Hulse, Jim
    Kamerud, John
    Lin, John
    Doughty, John
    Kurylak, Kai
    Tang, Daniel
    Buonarati, Mike
    Blanchette, Alexandre
    Levesque, Ann
    Gagnon-Carignan, Sofi
    Lin, Jenny
    Ray, Gene
    Liu, Yanseng
    Khan, Masood
    Xu, Allan
    el-Sulayman, Gibran
    DiMarco, Chantal
    Bouhajib, Mohammed
    Tacey, Dick
    Jenkins, Rand
    van der Strate, Barry
    Briscoe, Chad
    Karnik, Shane
    Rhyne, Paul
    Garofolo, Wei
    Schultz, Gary
    Roberts, Andrew
    Redrup, Mike
    BIOANALYSIS, 2014, 6 (22) : 2957 - 2963
  • [22] New US draft guidance issued for benefits, risks of opioids
    Reactions Weekly, 2019, 1760 (1) : 6 - 6
  • [23] Developing Drugs for Prevention of Chemotherapy-Induced Nausea and Vomiting: Draft Guidance from the FDA
    Lyons, Erica
    Line, Charles
    Lee, Jessica J.
    CLINICAL CANCER RESEARCH, 2021, 27 (22) : 6072 - 6074
  • [24] Updated US FDA draft guidance: ICH S9 nonclinical evaluation for oncotherapeutics
    不详
    BIOANALYSIS, 2009, 1 (02) : 271 - 271
  • [25] The US FDA Draft Guidance for Developing Abuse-Deterrent Opioid Analgesics: 2014 and Beyond
    Sellers E.M.
    Shram M.J.
    Schoedel K.A.
    Pharmaceutical Medicine, 2014, 28 (6) : 317 - 327
  • [26] Draft Guidance for Industry from FDA: Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product
    不详
    BIOTECHNOLOGY LAW REPORT, 2012, 31 (02) : 185 - 195
  • [27] Report of the AAPS Guidance Forum on the FDA Draft Guidance for Industry: “Drug Products, Including Biological Products, that Contain Nanomaterials”
    Jon S. B. de Vlieger
    Daan J. A. Crommelin
    Katherine Tyner
    Daryl C. Drummond
    Wenlei Jiang
    Scott E. McNeil
    Sesha Neervannan
    Rachael M. Crist
    Vinod P. Shah
    The AAPS Journal, 21
  • [28] Report of the AAPS Guidance Forum on the FDA Draft Guidance for Industry: "Drug Products, Including Biological Products, that Contain Nanomaterials"
    de Vlieger, Jon S. B.
    Crommelin, Daan J. A.
    Tyner, Katherine
    Drummond, Daryl C.
    Jiang, Wenlei
    McNeil, Scott E.
    Neervannan, Sesha
    Crist, Rachael M.
    Shah, Vinod P.
    AAPS JOURNAL, 2019, 21 (04):
  • [29] US FDA draft Guidance Standard for Clinical Trial Imaging Endpoints: more than just imaging?
    Walovitch, Richard C.
    Chokron, Patrick
    Agarwal, Sheela
    BIOMARKERS IN MEDICINE, 2012, 6 (06) : 839 - 847
  • [30] Recommendations for the Assessment of Blend and Content Uniformity: Modifications to Withdrawn FDA Draft Stratified Sampling Guidance
    Garcia, Thomas
    Bergum, James
    Prescott, James
    Tejwani, Ravindra
    Parks, Thomas
    Clark, Jon
    Brown, William
    Muzzio, Fernando
    Patel, Samir
    Hoiberg, Charles
    JOURNAL OF PHARMACEUTICAL INNOVATION, 2015, 10 (01) : 76 - 83
12345